Study: Commercially available antibodies used to investigate modification of key cancer braking mechanism aren’t fully reliable
Demsky joined the University of Michigan Rogel Cancer Center communications team in 2019. Prior to that he served as director of communications for the University of Michigan's Life Sciences Institute and science editor for Medicine at Michigan Magazine.
A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.
U-M researchers are shedding new light on the ways in which two omnipresent proteins can influence the fate of stem cells during development — with exciting implications for research and health.
Research suggests the possibility of a more general phenomenon, applicable to the growth of other primary cell types.
In mouse models, the work uncovers a new potential target to improve immunotherapy approaches to the deadly disease.